tradingkey.logo
tradingkey.logo
Search

aTyr Pharma Inc

ATYR
Add to Watchlist
0.559USD
-0.031-5.22%
Close 07/01, 16:00ETQuotes delayed by 15 min
54.80MMarket Cap
LossP/E TTM

TradingKey Stock Score of aTyr Pharma Inc

Currency: USD Updated: 2026-07-01

Key Insights

aTyr Pharma Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 108 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.86.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

aTyr Pharma Inc's Score

Industry at a Glance

Industry Ranking
108 / 387
Overall Ranking
233 / 4564
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

aTyr Pharma Inc Highlights

StrengthsRisks
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).
Growing
The company is in a growing phase, with the latest annual income totaling USD 190.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 190.00K.
Overvalued
The company’s latest PE is -0.80, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.62M shares, decreasing 28.92% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 17.02K shares of this stock.

Analyst Rating

Based on 9 analysts
Buy
Current Rating
4.857
Target Price
+713.86%
Upside Space

FAQs

How does TradingKey generate the Stock Score of aTyr Pharma Inc?

The TradingKey Stock Score provides a comprehensive assessment of aTyr Pharma Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of aTyr Pharma Inc’s performance and outlook.

How do we generate the financial health score of aTyr Pharma Inc?

To generate the financial health score of aTyr Pharma Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects aTyr Pharma Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of aTyr Pharma Inc.

How do we generate the company valuation score of aTyr Pharma Inc?

To generate the company valuation score of aTyr Pharma Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare aTyr Pharma Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of aTyr Pharma Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of aTyr Pharma Inc.

How do we generate the earnings forecast score of aTyr Pharma Inc?

To calculate the earnings forecast score of aTyr Pharma Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on aTyr Pharma Inc’s future.

How do we generate the price momentum score of aTyr Pharma Inc?

When generating the price momentum score for aTyr Pharma Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of aTyr Pharma Inc’s prices. A higher score indicates a more stable short-term price trend for aTyr Pharma Inc.

How do we generate the institutional confidence score of aTyr Pharma Inc?

To generate the institutional confidence score of aTyr Pharma Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about aTyr Pharma Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of aTyr Pharma Inc.

How do we generate the risk management score of aTyr Pharma Inc?

To assess the risk management score of aTyr Pharma Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of aTyr Pharma Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of aTyr Pharma Inc.